IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
IOL Chemicals and Pharmaceuticals filed the transcript of its Q4 FY24 earnings call held on May 16, 2024. For Q4 FY24, total income stood at Rs. 511 crore (vs Rs. 596 crore YoY), EBITDA at Rs. 58 crore with margins of 11.3% (down 620 bps YoY), and net profit at Rs. 28 crore. For full year FY24, revenue was Rs. 2,163 crore, EBITDA margins improved to 12.1% (up 90 bps from 11.2%), and net profit was Rs. 135 crore. Management guided FY25 revenue growth of 10-12%, EBITDA margins of 12-15%, PAT margins of 7-8%, and CAPEX of Rs. 150-200 crore funded internally. The company shared a longer-term aspiration to reach Rs. 3,000 crore in topline by FY28 from existing products and is acquiring new land near its Barnala facility for further expansion.
Management's forward guidance points to margin recovery in FY25 and a multi-year growth path to Rs. 3,000 crore revenue by FY28, which is constructive for the stock. However, near-term headwinds from pricing pressure in specialty chemicals (EBIT margin just 0.48% in Q4) and elevated freight costs from the Red Sea crisis remain concerns for the coming quarters.